Table 1 The demographics and characteristics of patients according to treatment received.

From: Comparison of treatment strategies and survival of early-onset gastric cancer: a population-based study

Variables

Total

Surgery only

SROC

SCRT

No surgery

P-value

n = 1639 (%)

n = 282 (17.2%)

n = 534 (32.6%)

n = 525 (32.0%)

n = 298 (18.2%)

Age groups, years, %

≤ 40 years

536 (32.7%)

84 (15.7%)

179 (33.4%)

176 (32.8%)

97 (18.1%)

0.834

41–45 years

509 (31.0%)

88 (17.3%)

169 (33.2%)

165 (32.4%)

87 (17.1%)

> 45 years

594 (36.2%)

110 (18.5%)

186 (31.3%)

184 (31.0%)

114 (19.2%)

Sex, %

Male

924 (56.4%)

140 (15.2%)

279 (30.2%)

309 (33.4%)

196 (21.2%)

 < 0.001

Female

715 (43.6%)

142 (19.9%)

255 (35.7%)

216 (30.2%)

102 (14.3%)

Race, %

White

1084 (66.1%)

187 (17.3%)

336 (31.0%)

343 (31.6%)

218 (20.1%)

0.104

Black

218 (13.3%)

38 (17.4%)

73 (33.5%)

77 (35.3%)

30 (13.8%)

Othersa

337 (20.6%)

57 (16.9%)

125 (37.1%)

105 (31.2%)

50 (14.8%)

Marital status, %

Married

993 (60.6%)

158 (15.9%)

339 (34.1%)

326 (32.8%)

170 (17.1%)

0.280

Unmarried

454 (27.7%)

85 (18.7%)

141 (31.1%)

136 (30.0%)

92 (20.3%)

Othersb

192 (11.7%)

39 (20.3%)

54 (28.1%)

63 (32.8%)

36 (18.8%)

Location, %

C16.0/C16.1

488 (29.8%)

43 (8.8%)

92 (18.9%)

197 (40.4%)

156 (32.0%)

 < 0.001

C16.2

200 (12.2%)

30 (15.0%)

95 (47.5%)

44 (22.0%)

31 (15.5%)

C16.3/C16.4

436 (26.6%)

99 (22.7%)

151 (34.6%)

156 (35.8%)

30 (6.9%)

C16.5/C16.6

253 (15.4%)

48 (19.0%)

93 (36.8%)

71 (28.1%)

41 (16.2%)

C16.8/C16.9

262 (16.0%)

62 (23.7%)

103 (39.3%)

57 (21.8%)

40 (15.3%)

Tumor size, %

 ≤ 3 cm

554 (33.8%)

160 (28.9%)

164 (29.6%)

155 (28.0%)

75 (13.5%)

 < 0.001

3.1–5.0 cm

460 (28.0%)

53 (11.5%)

148 (32.2%)

162 (35.2%)

97 (21.1%)

 > 5.0 cm

625 (38.1%)

69 (11.0%)

222 (35.5%)

208 (33.3%)

126 (20.2%)

Grade, %

I/II

321 (19.6%)

53 (16.5%)

70 (21.8%)

123 (38.3%)

75 (23.4%)

 < 0.001

III/IV

1318 (80.4%)

229 (17.4%)

464 (35.2%)

402 (30.5%)

223 (16.9%)

Histological type, %

Adenocarcinoma

1050 (64.1%)

162 (15.4%)

321 (30.6%)

349 (33.2%)

218 (20.8%)

 < 0.001

SRCC

563 (34.4%)

114 (20.2%)

207 (36.8%)

164 (29.1%)

78 (13.9%)

Othersc

26 (1.6%)

6 (23.1%)

6 (23.1%)

12 (46.2%)

2 (7.7%)

AJCC TNM stage, %

I

272 (16.6%)

162 (59.6%)

61 (22.4%)

33 (12.1%)

16 (5.9%)

 < 0.001

II

447 (27.3%)

43 (9.6%)

147 (32.9%)

210 (47.0%)

47 (10.5%)

III

540 (32.9%)

46 (8.5%)

210 (38.9%)

252 (46.7%)

32 (5.9%)

IV

380 (23.2%)

31 (8.2%)

116 (30.5%)

30 (7.9%)

203 (53.4%)

AJCC_T stage, %

T1

300 (18.3%)

148 (49.3%)

42 (14.0%)

34 (11.3%)

76 (25.3%)

 < 0.001

T2

172 (10.5%)

28 (16.3%)

65 (37.8%)

59 (34.3%)

20 (11.6%)

T3

626 (38.2%)

44 (7.0%)

196 (31.3%)

282 (45.0%)

104 (16.6%)

T4

541 (33.0%)

62 (11.5%)

231 (42.7%)

150 (27.7%)

98 (18.1%)

AJCC_N stage, %

N0

529 (32.3%)

187 (35.3%)

128 (24.2%)

110 (20.8%)

104 (19.7%)

 < 0.001

N1

433 (26.4%)

22 (5.1%)

133 (30.7%)

137 (31.6%)

141 (32.6%)

N2

303 (18.5%)

26 (8.6%)

109 (36.0%)

136 (44.9%)

32 (10.6%)

N3

374 (22.8%)

47 (12.6%)

164 (43.9%)

142 (38.0%)

21 (5.6%)

AJCC_M stage, %

M0

1259 (76.8%)

251 (19.9%)

418 (33.2%)

495 (39.3%)

95 (7.5%)

 < 0.001

M1

380 (23.2%)

31 (8.2%)

116 (30.5%)

30 (7.9%)

203 (53.4%)

Bone metastasis, %

Yes

42 (2.6%)

1 (2.4%)

6 (14.3%)

1 (2.4%)

34 (81.0%)

 < 0.001

No/unknown

1597 (97.4%)

281 (17.6%)

528 (33.1%)

524 (32.8%)

264 (16.5%)

Brain metastasis, %

Yes

6 (0.4%)

0 (0.0%)

1 (16.7%)

1 (16.7%)

4 (66.7%)

0.021

No/unknown

1633 (99.6%)

282 (17.3%)

533 (32.6%)

524 (32.1%)

294 (18.0%)

Liver metastasis, %

Yes

100 (6.1%)

8 (8.0%)

12 (12.0%)

4 (4.0%)

76 (76.0%)

 < 0.001

No/unknown

1539 (93.9%)

274 (17.8%)

522 (33.9%)

521 (33.9%)

222 (14.4%)

Lung metastasis, %

Yes

29 (1.8%)

1 (3.4%)

3 (10.3%)

0 (0.0%)

25 (86.2%)

 < 0.001

No/unknown

1610 (98.2%)

281 (17.5%)

531 (33.0%)

525 (32.6%)

273 (17.0%)

  1. Othersa: American Indian/AK Native, Asian/Pacific Islander, unknown; Othersb: Divorced, Separated, Widowed, unknown; SRCC: signet ring cell carcinoma; Othersc: cystic, mucinous and serous neoplasms; SROC: surgery plus radiotherapy or chemotherapy; SCRT: surgery plus chemoradiotherapy; C16.0/C16.1: Cardia, NOS/Fundus of stomach; C16.2: Body of stomach; C16.3/C16.4: Gastric antrum/ Pylorus; C16.5/C16.6: Lesser curvature of stomach NOS/Greater curvature of stomach NOS; C16.8/C16.9: Overlapping lesion of stomach/ Stomach, NOS.
Back to article page